Bausch + Lomb progresses dry eye candidate to Phase III despite mixed data

Two of Bausch + Lomb's candidates will now head to their next clinical stages of development in dry eye and ocular pain, respectively. Two ophthalmic candidates will now head to their next clinical stages of development in dry eye and ocular pain, respectively. Bausch + Lomb has chosen to advance two of its pharmaceutical assets further down the clinical pipeline, despite one of the drugs posting mixed data. The first therapy the Canadian company will progress is its eye drop designed to treat dry eye, which will advance to Phase III development after the medicine showed efficacy in certain aspects…

Source: Clinical Trials Arena